A Phase I Study of Eribulin, a Novel Microtubule Inhibitor, in Children With Refractory or Recurrent Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Eribulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms ERIBULIN
- 29 Mar 2017 Planned End Date changed from 1 Dec 2015 to 1 Jun 2018.
- 29 Mar 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2018.
- 10 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.